Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03006614
Other study ID # 2014-FXY-077-??
Secondary ID
Status Recruiting
Phase Phase 3
First received April 28, 2016
Last updated January 13, 2017
Start date April 2016
Est. completion date March 2023

Study information

Verified date January 2017
Source Sun Yat-sen University
Contact YanXia Shi, doctor
Phone 02087343488
Email shiyanxia@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to explore new PERS prediction model can improve the pathological complete response rate of neoadjuvant chemotherapy of breast cancer and disease-free survival.


Description:

This is a multi-center, prospective, randomized phase III clinical trial. Planning 320 cases.

This study will be divided into two stages. Phase one, 120 cases of local advanced breast cancer (LABC)who need neoadjuvant chemotherapy. Gene prediction model test(PERS) is performed before treatment(ddEC-T+/-H), verify the prediction efficacy of PERS.

Phase two, 200 cases of LABC primary resistant of antharcycline and taxans. Patients were randomized to Arm ddEC-T+/-H and Arm PERS (regimens according to PERS,eg NVB+DDP,capacitabine,gemcitabine and so on) pCR rate and DFS is observed.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date March 2023
Est. primary completion date March 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion criteria: all of the patients in the trial need to meet

- age: at least 18 years old;

- ECOG(Eastern Cooperative Oncology Group) scoring =1;

- confirmed by histology or cytology breast infiltrating ductal carcinoma

- agreed to breast cancer tissue biopsy

- here is a new adjuvant chemotherapy against patients with stage II/III

- According to RECIST criteria, target lesion in patients with at least one, at least one single diameter measurable lesions .Is defined as a measurable lesions with the following method can accurately measure at least one of the diameter of the lesion: lesions or greater diameter 20 mm or measured in conventional methods spiral CT measurement lesions 10 mm diameter or greater. Positron emission tomography (CT) and ultrasound can not be used as measurement method lesions.

- The normal numerical laboratory: The patient's level of organ function must meet the following requirements: enough reserves: bone marrow neutrophils (cent leaves and ribbon neutrophils) absolute count (ANC) =1.5*109 / L, or platelets= 100*109 / L, or acuity = 9 g/dL and hemoglobin.Liver: bilirubin < 1.5 times the upper limit of normal, alkaline phosphatase (AP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 times the upper limit of normal (If allowed to AP with liver metastasis, AST, ALT < 5 times the upper limit of normal).Kidney: creatinine clearance or 45 mL/min.

- Signed informed consent;

- is expected to survival in patients with 3 or more months.

- patient adherence and geographic location of residence meet the needs of the follow-up.

- in the research into the group of 7 days before the serum or urine pregnancy test must be negative, and must be for the nursing of patients.Or sterilization surgery, patients after menopause, or agreed to in the research during the treatment and research within 6 months after the end of the treatment period using an approved by the medical contraception (such as intrauterine device (IUD), pill or condoms)

Exclusion Criteria:

- ECOG(Eastern Cooperative Oncology Group) scoring =2 ;

- At the same time to accept any other anti-tumor treatment.

- In the past 12 months have congestive heart failure, drug treatment can't control history of arrhythmia, myocardial infarction, etc;

- The serious, which has not been controlled intercurrent infection, organ dysfunction, or serious metabolic disorder of patients;

- Active infection (decided by the researchers.

- According to the researcher's judgment, there is serious to endanger the safety of patients, or patients completed the research associated with disease.

- Pregnancy or breast-feeding women.

- Always have a clear history of neurological or psychiatric disorders, including epilepsy, or dementia.

- A history of other tumors or combined with other tumor patients.

- Before study enrollment for any reason within 30 days of use had not been approved by the local drug ;

- Unwilling or unable to continue to comply with the experimental program, or can not cope with patients follow-up;

- Researchers think that is unfavorable to the participants.

Study Design


Intervention

Drug:
NVB

EPI

DDP

CAP

GEM

H

CTX

T


Locations

Country Name City State
China Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shi Yanxia

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of participants with treatment-related adverse events as assessed by NCI(National Cancer Institude) CTC (Clinical Trials Center)v3.0 Safety evaluation up to 96 months
Primary Surgical specimens of breast primary tumors and axillary lymph nodes as measured by Pathological examination. pCR(pathologic complete response) up to 96 months
Secondary Time as a measure from randomization to disease recurrence or patients died due to disease progression. DFS(Disease-free survival) up to 96 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A